A phase 2 placebo-controlled study in skin-predominant DM patients demonstrated that the use of an IFNβ-specific antibody significantly decreased patients’ CDASI-A level at week 12 from baseline with mild adverse effects7. The gene discussed is IFNB1; the disease is dermatomyositis.